0.05),but 5-Aza at the concentration of 15?mol/L inhibited the growth of MSCs(P

Objective To analyze the expression of KCNJ11 mRNA in gliomas and its prognostic value. Methods The clinical, histopathological and molecular pathological features of 273 patients with gliomas were collected from CGGA. We analyzed the differences of KCNJ11 mRNA expression in different types of gliomas and the survival time of patients with high and low expression of KCNJ11 mRNA in different subtypes of gliomas. Results The expression levels of KCNJ11 mRNA in young glioma and primary glioma patients were higher than those in old glioma and recurrent glioma patients, respectively (P=0.008, 0.001). The expression of KCNJ11 mRNA in oligodendroglioma was the highest, astrocytoma was the second, and glioblastoma was the lowest (P=0.000). The expression of KCNJ11 mRNA in WHOⅡ grade glioma was the highest, WHOⅢ was the second, and WHOⅣ was the lowest (P=0.000). The expression levels of KCNJ11 mRNA in IDH-mutant type glioma patients were higher than those in IDH-wild type glioma patients (P=0.000). The expression of KCNJ11 mRNA in deletion of 1p/19q glioma patients was higher than that in non-deletion of 1p/19q ones (P=0.000). The expression of KCNJ11 mRNA in MGMT methylated glioma patients was higher than that in non-methylated ones (P=0.036). The survival time of patients with high expression of KCNJ11 mRNA (≥2.77) was longer than that with low expression (P=0.000). Multivariate Cox analysis showed that the high expression of KCNJ11 mRNA was an independent factor affecting the good prognosis of patients with glioma. Conclusion The expression of KCNJ11 mRNA is negatively related to the malignant degree of the tumor. The high expression of KCNJ11 mRNA is an independent factor affecting the good prognosis of patients with glioma.

BACKGROUND:Osteonecrosis of the femoral head is a common orthopedic disease,and hip preservation surgery with bone grafting is commonly used in the early stage,in which autologous bone and allograft bone are commonly used as bone grafting materials.However,autologous bone transplantation is highly traumatic and bone supply is limited,and allograft bone is rich in sources,but there are serious risks of immune rejection and absorption.In recent years,the tissue engineering technique based on mesenchymal stem cells is a new method for the treatment of femoral head necrosis,which is gradually widely used after basic experiments and clinical application. OBJECTIVE:To review the application and prospect of tissue engineering in the treatment of osteonecrosis of the femoral head to provide a new choice for the clinical treatment of osteonecrosis of the femoral head. METHODS:The PubMed database and CNKI database from 2013 to 2023 were searched by the first author with Chinese and English search terms"tissue engineering,mesenchymal stem cells,biological scaffolds,cytokines,osteonecrosis of the femoral head,bone graft,hip preservation".The articles on the treatment of osteonecrosis of the femoral head with tissue engineering technology were selected,and 55 representative articles were included for review after the initial screening of all articles according to the inclusion and exclusion criteria. RESULTS AND CONCLUSION:(1)With the continuous development of biotechnology and materials science,great progress has been made in the treatment of osteonecrosis of the femoral head by bone tissue engineering,such as the application of gene-modified mesenchymal stem cells to repair osteonecrosis,the combination of gene recombination technology and surface modification technology with bone tissue engineering in the treatment of osteonecrosis of the femoral head.(2)When applied to the necrotic femoral head,tissue engineering technology can promote the regeneration of necrotic bone tissue and the repair of the vascular system,provide biomechanical stability for the necrotic area,and use bioactive factors to accelerate the repair of seed cells to complete the regeneration of new bone in necrotic area.(3)However,most of these studies are still in the animal experiment stage,and there are still many unsolved problems and challenges in bone tissue engineering research.With the rapid development of nanotechnology,tissue engineering and clinical medicine,biomimetic replacement bone grafting materials with perfect performance are expected to come into being.(4)In the future,bone tissue engineering for osteonecrosis of the femoral head is expected to be a satisfactory treatment for patients with hip preservation.

Objective:To study the mRNA expressions of bone morphogenetic protein 2 ( BMP2) in different types of gliomas and the relation between BMP2 mRNA expression and survival time, and to explore the role of BMP2 mRNA expression in prognosis evaluation in gliomas. Methods:The clinical data of 692 patients with gliomas in China Glioma Genome Atlas (CGGA) database were collected. Differences of BMP2 mRNA expression were compared among glioma patients with different histophiologic types, and patients with different gender and different ages, patients at primary or recurrent status, and those with different WHO grading, isocitrate dehydrogenase 1 (IDH1) mutation, 1P19q heterozygous deletion status, and molecular typing. The difference in survival time between patients with high and low BMP2 mRNA expression levels were compared in different categories of gliomas. Results:(1) The BMP2 mRNA expressions were different in different histopathological types of gliomas ( F=9.392, P=0.000); BMP2 expression in the oligodendroglioma subtype was the highest, followed by astrocytoma subtype and glioblastoma. The BMP2 relative mRNA expressions in male and female patients were 9.78±0.65 and 11.26±0.86, respectively, without statistical difference ( P>0.05). The BMP2 relative mRNA expressions in patients <43 years old and patients≥43 years old were 12.51±0.81 and 8.37±0.65, respectively, with significant difference ( P<0.05). The BMP2 relative mRNA expressions were 10.09±0.62 and 10.90±0.93, respectively, without significant difference ( P>0.05). The BMP2 relative mRNA expressions were 13.98±1.12, 12.88±0.88 and 5.18±0.64 in WHO grading II, III, and IV gliomas patients, respectively, with significant differences ( F=30.912, P=0.000). The BMP2 relative mRNA expressions in patients with IDH1 wild-type and IDH1 mutant were 2.73±0.16 and 17.47±0.85, respectively, with significant difference ( P<0.05). The BMP2 relative mRNA expressions in patients with 1P/19Q non-absence and 1P/19Q absence were 7.02±0.36 and 25.28±1.66, respectively, with significant difference ( P<0.05). In patients with lower graded glioma and glioblastoma, the BMP2 mRNA expressions in these patients with IDH mutation were significantly higher than those in patients with IDH wild-type ( P<0.05). (2) In patients with primary glioma and patients with recurrent glioma, the survival time of these patients with high BMP2 mRNA expression (≥4.68) was significantly longer than that of patients with low expression (<4.68, χ2=62.975, P=0.000; χ2=12.810, P=0.000). Conclusion:The BMP2 mRNA expression can be used as an index to predict the malignant degrees of gliomas; patients with high expression have longer survival time than those with low expression.

Objective:To analyze the expression of ATP binding cassette subfamily C member 8 (ABCC8) in different types of gliomas and its relation with overall survival of glioma patients.Methods:The ABCC8 mRNA data and clinical data (gender, age, histopathology, WHO grading, isocitrate dehydrogenase [ IDH] mutation status, 1p/19q deletion status and molecular types), and overall survival of 516 glioma patients from the Cancer Genome Atlas were collected, and the differences of ABCC8 mRNA expression in different types of glioma patients were compared. The differences of overall survival were compared between high (≥54.50) and low (<54.50) ABCC8 mRNA expression patients in different types of glioma patients. Results:(1) ABCC8 mRNA expression in primary glioma patients was significantly higher than that in recurrent glioma patients ( P<0.05). ABCC8 mRNA expression was the highest in oligodendroglioma patients, followed by astrocytoma patients; and glioblastoma patients had the lowest ABCC8 mRNA expression; the differences among glioma patients from subgroups of different histopathological types were statistically significant ( P<0.05). ABCC8 mRNA expression was the highest in patients with grade II glioma, followed by those with grade III ( P<0.05); and patients with grade IV had the lowest ABCC8 mRNA expression ( P<0.05); the differences among patients from subgroups of different WHO grading were statistically significant ( P<0.05). ABCC8 mRNA expression in glioma patients with IDH mutant was significantly higher than that in glioma patients with IDH wild-type ( P<0.05); and ABCC8 mRNA expression in patients with 1P/19Q deletion glioma was significantly higher than that in patients with 1P/19Q deletion ( P<0.05). ABCC8 mRNA expression in low-grade glioma patients and glioblastoma multiforme patients with IDH mutation was significantly higher than that in patients with IDH wild-type ( P<0.05). (2) In all patients with glioma, primary and recurrent glioma, oligodendroglioma, neuroastrocytoma, WHO low-grading (grade II) and WHO high-grading (grade III or IV) glioma, IDH mutation and IDH wild-type gliomas, and 1p/19q deletion and no deletion gliomas, patients with high ABCC8 mRNA expression had significantly higher overall survival time that those with low ABCC8 mRNA expression ( P<0.05). (3) Multivariate Cox analysis showed that ABCC8 mRNA expression was an independent factor for overall survival of patients with gliomas ( HR=0.747, P=0.025, 95%CI:0.579-0.963). Conclusion:The ABCC8 mRNA expression in glioma patients is related to the malignant degrees of gliomas, which can be used as an indicator to predict the prognoses of gliomas.